Related Experiment Video
Updated: Jun 6, 2025
05:18
Acupoint Catgut Embedding Therapy for Abdominal Obesity Treatment
Published on: November 22, 2024
428
[Percutaneous gastric embolization for obesity: A prospective mid-term outcomes study]
Carlos Ivan Soledispa Suárez1, Robert Alarcón Cedeño2, Luis Mariano de la Torre Fonseca3
1Unidad de Cardiología Intervencionista, Departamento de Cardiología, Instituto de Salud Cardiovascular (Isac-Med), Guayaquil, Ecuador.
Medicina Clinica
|November 27, 2024
Summary
Percutaneous gastric embolisation (PGE) effectively reduces BMI in obese patients. This safe and well-tolerated procedure shows high success rates and sustained weight loss with minimal complications.
Area of Science:
- Interventional Cardiology
- Bariatric Procedures
- Public Health
Background:
- Obesity is a global health crisis with increasing prevalence.
- Existing prevention strategies are insufficient to curb rising obesity rates.
- Percutaneous gastric embolisation (PGE) is an emerging interventional treatment for obesity.
Purpose of the Study:
- To evaluate the efficacy and safety of PGE in managing severe obesity.
- To assess weight loss outcomes and complication rates associated with PGE.
Main Methods:
- Prospective longitudinal cohort study.
- Inclusion of 15 patients with grade III obesity.
- Procedure performed at the Cardiovascular Health Institute in 2022.
Main Results:
- 86.7% of PGE procedures were successful.
- Significant weight loss observed at 6 months post-procedure (P<.001).
- No major vascular complications, gastric ulcers, or ischemia reported; common side effects included nausea and epigastralgia.
Conclusions:
- PGE is an effective and safe bariatric procedure.
- The treatment leads to significant BMI reduction and sustained results.
- PGE is well-tolerated by obese patients with a high success rate.
